UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2017
ELEVEN BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
| | | | |
| | | | | |
| Delaware | | 001-36296 | | 26-2025616 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
245 First Street, Suite 1800 Cambridge, MA | | 02142 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (617) 444-8550
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| |
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
| ¨ | Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12) |
|
| |
| ¨ | Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b)) |
|
| |
| ¨ | Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c)) |
Item 8.01 Other Events.
On April 2, 2017, Eleven Biotherapeutics, Inc. (the “Company”) announced new preclinical data with VB4-845, the active pharmaceutical ingredient used to formulate ViciniumTM and ProxiniumTM, and deBouganin, the de-immunized payload used in the Company’s systemically-administered drug candidates. These data were presented at the American Association of Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
| |
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
| | |
| | | |
Exhibit No. | | Document |
| | |
| 99.1 | | Press release of Eleven Biotherapeutics, Inc., dated April 2, 2017. |
| | | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 3, 2017
|
| | |
| | | |
| Eleven Biotherapeutics, Inc. |
| | |
| By: | | /s/ John J. McCabe |
| | | John J. McCabe |
| | | Chief Financial Officer |
EXHIBIT INDEX
|
| | |
| | | |
Exhibit No. | | Document |
| | |
| 99.1 | | Press release of Eleven Biotherapeutics, Inc., dated April 2, 2017. |
| | |
| | | |
